The following are the major changes made to Berkshire Hathaway’s stock portfolio during the third quarter of 2021.
Q3 2021 hedge fund letters, conferences and more
New Positions:
(1) Royalty Pharma plc (+$475 million)
(2) Floor and Decor Holdings (+$100 million)
Addition to Positions:
(1) Chevron (+$560 million) (24% of stake)
Position Sold:
(1) Merck (-$750 million)
Position Reductions:
(1) Charter Communications (-$700 million) (19% of stake)
(2) AbbVie (-$600 million) (30% of stake)
(3) Bristol-Myers Squibb (-$250 million) (16% of stake)
(4) Marsh & McLennan (-$200 million) (35% of stake)
(5) U.S. Bancorp (-$150 million) (2% of stake)
Article by Dr. David Kass